Constipation is the fourth most frequently reported adverse event in the Ozempic (semaglutide) Phase 3 program, affecting roughly 15–24% of patients at label doses. It is not usually dangerous, but it is persistent — and the mechanism (GLP-1 receptor-mediated slowing of gut motility) means routine laxatives often underperform. This review walks through the trial data, the biology, and seven research-backed remedies that address the cause.
Key Takeaways
- Rates scale with dose. STEP-1 reported constipation in ~24% of participants on semaglutide 2.4 mg versus ~11% on placebo.
- The mechanism is slow transit. GLP-1 receptor activation reduces gastric emptying and colonic motility — the whole gut is slower.
- Fiber + fluid is first line. Low-FODMAP soluble fiber plus 2–3 L of fluid daily resolves most mild cases within 1–2 weeks.
- Osmotic laxatives work; stimulants often do not. Polyethylene glycol (PEG 3350) outperforms senna or bisacodyl because the issue is slow transit, not blocked emptying.
- Walking helps. 20–30 minutes of brisk walking after meals accelerates colonic transit measurably.
- Severe constipation + abdominal pain = clinical review. Rare but serious events (ileus, gastroparesis complications) do happen.
How common is Ozempic constipation?
The Phase 3 STEP program and the T2D SUSTAIN program both reported constipation as a top-five adverse event. Rates scaled with dose and persisted beyond the typical GI dose-escalation window.
| Trial / dose | Constipation rate | Placebo rate | Discontinuation for constipation |
|---|---|---|---|
| STEP-1 (semaglutide 2.4 mg, obesity) | ~24% | ~11% | <0.5% |
| STEP-2 (semaglutide 2.4 mg, T2D + obesity) | ~15–17% | ~8% | <0.5% |
| SUSTAIN-6 (semaglutide 1.0 mg, T2D CV) | ~11% | ~5% | <0.3% |
| SUSTAIN-7 (semaglutide 1.0 mg vs dulaglutide) | ~13% | n/a | <0.3% |
Two patterns stand out. First, constipation on semaglutide is roughly twice the placebo rate. Second, discontinuation specifically for constipation is uncommon — most patients manage the symptom and stay on treatment. In STEP-1, overall GI-related discontinuation was approximately 4.5%; constipation was a minority of that.
Why Ozempic slows the gut
GLP-1 receptors are expressed throughout the gastrointestinal tract — in the stomach, small intestine, and colon. Activation of these receptors reduces smooth-muscle contractility and slows transit time. The best-characterized effect is gastric emptying delay (which drives nausea and the appetite-suppression effect). Less-discussed but just as real is colonic transit slowing, which drives constipation.
A clinical study of GLP-1 receptor agonists measured whole-gut transit time increases of 20–60% versus placebo, with the largest effect in the colon. In practical terms, stools become drier and harder because they spend longer in the colon, where water is reabsorbed.
This mechanism explains why routine stimulant laxatives often disappoint. Senna and bisacodyl increase colonic contractility, but if the GLP-1 is actively suppressing that contractility, the signal is competing with the drug. Osmotic laxatives (which draw water into the colon independently of motility) work much better.
Seven research-backed remedies
Here are the remedies most consistent with the mechanism and the clinical trial data. They are listed from first-line to last-resort.
1. Hydrate above baseline (first line)
GLP-1 drugs reduce appetite and often food intake, which drops water intake. Dehydration directly worsens constipation. Target 2–3 L of fluid daily (coffee and tea count); more if active or in a hot climate.
2. Soluble fiber, not insoluble (first line)
Psyllium husk (3–10 g daily, titrated up slowly) adds water-holding capacity to stool and is better tolerated on GLP-1 drugs than wheat bran, which can bulk uncomfortably on top of slowed transit. Start at 3 g with water and increase over a week.
3. Walking after meals
Twenty to thirty minutes of brisk walking after each main meal measurably accelerates colonic transit. This is one of the few non-drug interventions with controlled trial support in GLP-1-induced constipation.
4. Osmotic laxative — PEG 3350
Polyethylene glycol 3350 (Miralax, generic brands) is the preferred OTC osmotic laxative. Standard dose is 17 g daily dissolved in 240 mL fluid. It works by drawing water into the colon regardless of motility and is safe for long-term use.
5. Magnesium citrate or magnesium oxide
Magnesium salts are osmotic and have a mild stool-softening effect. 300–400 mg magnesium citrate at bedtime is a common OTC option. Avoid at renal insufficiency.
6. Dose reduction or re-titration
If constipation is severe and the other measures fail, dropping back one dose tier (e.g., 2.4 mg → 1.7 mg or 1.0 mg → 0.5 mg) for 2–4 weeks and then re-escalating is a label-sanctioned maneuver. Many patients tolerate the re-escalation without the constipation returning.
7. Prescription options (last line)
Linaclotide, lubiprostone, and prucalopride are prescription agents that act on gut-motility and secretion pathways. They are second-line for chronic idiopathic constipation and reasonable for refractory GLP-1-related constipation under clinician review.
What usually does not work
A short list of commonly tried interventions with limited evidence on GLP-1-slowed guts:
- Stimulant laxatives (senna, bisacodyl) — competes with the drug's motility suppression; often disappointing. Reasonable as rescue, not standing therapy.
- Insoluble wheat bran — bulks stool but does not help transit; can worsen bloating.
- Probiotics as monotherapy — mixed evidence; may help microbiome composition over months but will not clear acute constipation.
When to call a clinician
Most Ozempic constipation is a nuisance, not an emergency. A clinician should be contacted if any of the following appear:
- Severe abdominal pain, especially with distension or vomiting (consider ileus or bowel obstruction).
- No bowel movement for more than 5–7 days despite the measures above.
- Blood in stool, dark tarry stool, or new rectal bleeding.
- Signs of dehydration — dizziness on standing, concentrated urine, confusion.
Rare but documented serious events on the GLP-1 class include ileus and small-bowel obstruction. Any severe acute presentation deserves clinical review.
Conclusion
Ozempic constipation is common, mechanistic, and manageable. It happens because the drug slows the whole gut — not just the stomach — and routine stimulant laxatives often underperform because they fight the drug directly. The first-line response is dehydration correction, soluble fiber, and walking; the second line is an osmotic laxative like PEG 3350; and the third line is dose adjustment or prescription motility agents. The vast majority of patients find a combination that works within 1–3 weeks without stopping the drug.
Frequently Asked Questions
How common is constipation on Ozempic?
Approximately 15–24% of patients on the semaglutide 2.4 mg Phase 3 obesity dose and 11–13% on the 1.0 mg T2D dose. Both are roughly double the placebo rate.
Does Ozempic constipation go away?
Often yes, within a few weeks of either dose stabilization or routine use of fiber plus an osmotic laxative. Some patients remain mildly constipated throughout treatment.
What is the best laxative for Ozempic constipation?
Polyethylene glycol 3350 (Miralax, generic brands) is the preferred first-line because it works via osmosis, not motility, and is safe for long-term use.
Why do stimulant laxatives not work as well on Ozempic?
Stimulant laxatives like senna and bisacodyl increase colonic contractility — the exact pathway GLP-1 agonists suppress. They often disappoint for standing use.
Does drinking more water help with Ozempic constipation?
Yes. GLP-1 drugs reduce appetite and often fluid intake; hydration below ~2 L per day worsens constipation. Target 2–3 L daily.
Can Ozempic cause bowel obstruction?
Rare but documented. Severe abdominal pain, distension, or vomiting with constipation warrants urgent clinical review.
Primary sources:
- STEP-1: Semaglutide 2.4 mg in obesity — NEJM 2021
- SUSTAIN-6: Semaglutide cardiovascular outcomes — NEJM 2016
- SUSTAIN-7: Semaglutide vs dulaglutide — Lancet Diabetes 2018
- GLP-1 agonists and gastrointestinal motility — Diabetes Obes Metab 2019
- AGA guideline on chronic idiopathic constipation
Research disclaimer: This article is a research review for educational use only. It is not medical advice. Severe or persistent constipation should be evaluated by a qualified clinician. Semaglutide (Ozempic, Wegovy, Rybelsus) is FDA-approved for specific indications; use outside the approved indication, dose, or route should be discussed with a licensed prescriber.
Sources & Further Reading
Peer-reviewed clinical trial data and research publications underpinning this article. See our full research library.
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384:989–1002. Phase 3 RCT
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine, 389:2221–2232. Phase 3 RCT
